Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/15/2018
Start Date:June 19, 2018
End Date:June 2022
Contact:Ambereen Yousuf
Email:ayousuf@radiology.bsd.uchicago.edu
Phone:(773) 702-6003

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

MRI Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

The purpose of the proposed research is to test and validate an artificial intelligence-based
Risk Map decision-support system (DSS) for prostate cancer Magnetic Resonance Imaging (MRI)
interpretation and identification of clinically significant tumor site(s).


Inclusion Criteria:

- Patients with known or suspected prostate cancer who have been referred to the
Department of Radiology at the University of Chicago Medical Center for a diagnostic
MRI exam of the prostate, to be followed by an MRI-guided fusion biopsy of the
prostate.

- Written informed consent.

Exclusion Criteria:

- Patients incapable of giving informed written consent;

- Patients who cannot adhere to the experimental protocols for any reason, or have an
inability to communicate with the researcher;

- Patients with psychiatric disorders that affect their ability to consent for
themselves will be excluded and not the entire population of patients with psychiatric
disorders.

- Prisoners;

- Minor children (under the age of 18 years old).
We found this trial at
1
site
University of Chicago Medical Center
5841 S Maryland Ave
Chicago, Illinois 60637
(773) 702-1000
Phone: 773-702-6003
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
?
mi
from
Chicago, IL
Click here to add this to my saved trials